Form 10-Q Intra-Cellular Therapies For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- Wall Street ends down as US-Iran peace optimism fades
- eToro to acquire TradeZero for up to $231M to expand in US
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Intra-Cellular Therapies (ITCI) PT Lowered to $96 at RBC Capital
May 7, 2024 12:44 PM EDTRBC Capital analyst Brian Abrahams lowered the price target on Intra-Cellular Therapies (NASDAQ: ITCI) to $96.00 (from $100.00) while maintaining a Outperform rating.
The analyst comments "This morning ITCI reported 1Q24 earnings and we had a chance to catch up with mgmt to... More
JPMorgan on Intra-Cellular Therapies (ITCI): 'We continue to like ITCI stock'
May 7, 2024 12:32 PM EDTJPMorgan analyst Jessica Fye reiterated an Overweight rating and $75.00 price target on Intra-Cellular Therapies (NASDAQ: ITCI)
The analyst comments "We continue to like ITCI stock on the back of solid 1Q results and with shares having come off of their post-data highs. ITCI reported 1Q24 revenue of $145mm,... More
Jefferies Positive on Intra-Cellular Therapies (ITCI): 'We like the setup ahead of the second MDD readout in late-Q2'
May 7, 2024 8:00 AM EDTJefferies analyst Andrew Tsai reiterated a Buy rating and $105.00 price target on Intra-Cellular Therapies (NASDAQ: ITCI).
The analyst comments "ITCI previously preannounced a Q1 beat (Caplyta sales were $145M vs cons $141M), and mgmt just reiterated its 2024 guidance of $645-675M. Quarterly... More
